Navigation Links
Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1

ients."

About Omega DUROS Therapy

Omega DUROS therapy is being developed to improve the treatment of HCV by offering a more convenient and potentially safer and more effective treatment. Omega DUROS therapy is designed to deliver a continuous and consistent dose of omega interferon for three months via the implantable DUROS device, a drug delivery technology developed by ALZA Corporation, and licensed to Intarcia for use in certain broad fields. Another product incorporating the DUROS technology has already approved by the FDA for the palliative treatment of prostate cancer. Intarcia is also leveraging the DUROS technology in evaluating other drug development opportunities. The most advanced of these is focused on the delivery of GLP-1 and a GLP-1 analog with the DUROS device for the treatment of type 2 diabetes.

About Intarcia

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with chronic diseases in which there are significant unmet medical needs. Intarcia's drug development expertise and competitive edge are complemented by its ability to stabilize macromolecules and to deliver them in a constant and consistent manner via the proprietary DUROS drug delivery platform. The initial programs that Intarcia is pursuing are in hepatitis C and type 2 diabetes.

About Hepatitis C

Hepatitis C is a major global public health problem. According to the World Health Organization, more than 170 million people worldwide are chronically infected with HCV, and three to four million new HCV infections occur annually. The U.S. Centers for Disease Control and Prevention has estimated that in the United States approximately 3.4 million people are chronically infected with HCV and approximately 25,000 new patients are infected each year. It is estimated that 10,000 to 12,000 patients die annually in the United States from complications resulting from HCV infection. The current standard of care for tr
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:9/19/2014)... Research and Markets ... of the "Global Gynecological Devices Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... wide categories based on their operations. These ... different gynecological conditions that affect the female ...
(Date:9/19/2014)... TRIANGLE PARK, N.C. , Sept. 19, 2014 ... focused on cloud-based drug design and development, partnering ... The company,s mission is to design new drugs ... 1 and 2 partners to further their development. ... its portfolio investments. To support this business model, ...
(Date:9/19/2014)... , Sept. 19, 2014 The American Association ... Medical Design and Manufacturing has joined the AAHomecare Corporate ... Harvey Diamond have been actively involved in ... as it has quickly grown into a major global ... like Drive allows AAHomecare to increase efforts on behalf ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Inc. (NASDAQ: DCTH ) announced today that management ... Conference on Tuesday, August 16, 2011 at 2:25 P.M. ET ... an overview of the Company,s business strategy and recent corporate ... invitation only. Delcath will offer a live audio webcast of ...
... 10, 2011 Leading events organizers UBM Canon ... (LSE: UBM), today announced a virtual conference event which will examine ... chain, counterfeit drugs. Titled ,Pharmaceutical Track & Trace Authentication: The Fight ... from 6:00 to 14:00 New York time, 12:00 to 20:00 Paris ...
Cached Medicine Technology:Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 3UBM Canon Introduces a Compelling New Virtual Conference Focused on Track & Trace Solutions for the Pharma Sector 2UBM Canon Introduces a Compelling New Virtual Conference Focused on Track & Trace Solutions for the Pharma Sector 3
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- The U.S. Food and Drug ... Thursday. Trulicity is part of a class of once-a-week injectable ... type 2 diabetes. "Trulicity is a new treatment ... treatment regimens to control blood sugar levels in the overall ... of the FDA,s Office of Drug Evaluation II, said in ...
(Date:9/19/2014)... cells to treat and cure disease is a ... hindered by the inability of doctors and scientists to ... cells in patients without resorting to invasive procedures, like ... in the online journal Magnetic Resonance in Medicine ... School of Medicine, University of Pittsburgh and elsewhere describe ...
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- More states are ... medication epinephrine to use for any child having a ... treatment for "anaphylaxis," an allergic reaction that can lead ... blood pressure and even death. In people ... or tree nuts, insect venom or certain drugs, anaphylaxis ...
(Date:9/19/2014)... 19, 2014 Top 10 Best ... announced that HostGator.com, GoDaddy and Bluehost are among ... companies are the most recommended suppliers for webmasters ... to buy high quality Linux hosting (including VPS ... is one of many top hosting companies that ...
Breaking Medicine News(10 mins):Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:A better way to track emerging cell therapies using MRIs 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:Top10BestSEOHosting.com Announces Great Linux Web Hosting Suppliers In 2014 2
... REMIND LAWMAKERS CALIFORNIA PREMIUMS ARE 17 PERCENT ... ... At the Assembly,Health Committee,s hearing on Governor Arnold Schwarzenegger,s health ... National Association of Insurance and Financial Advisors-California,(NAIFA-California) urged lawmakers to ...
... 31 Conseco, Inc. (NYSE:,CNO) today reported results for ... reflect a number of significant events, as,progress on our ... increasingly evident," CEO Jim Prieur said. "We saw continued,strong ... businesses, while,Conseco Insurance Group, even with a decline in ...
... Effective ... Alternatives, LOS ... thinking about health and medicine over the past few years as ... As concerns grow regarding conventional, over-the-counter,medicine, Hyland,s homeopathic medicines offer a ...
... Dr. James M. Farrell, a,doctor of chiropractic practicing ... Chiropractic Association (CCA). He was nominated,and chosen by his ... the CCA since 1992, Dr. Farrell has been extremely ... a committee chair, board member,and executive board member prior ...
... Today researchers report a newly identified genetic ... cancer in African American men. This study, which ... prostate cancer in high-risk populations, is published online in ... cancer is the second leading cause of cancer death ...
... feline DNA could help humans, too, scientists say , WEDNESDAY, ... of the domestic cat ( Felis catus ), an advance ... pets and provide an excellent model for human disease. , ... traced back several generations to Sweden, was the subject of ...
Cached Medicine News:Health News:Health Insurance Agents Warn Against Imposing a 'Health Care Reform' Tax in California 2Health News:Health Insurance Agents Warn Against Imposing a 'Health Care Reform' Tax in California 3Health News:Conseco Reports Third Quarter Results 2Health News:Conseco Reports Third Quarter Results 3Health News:Conseco Reports Third Quarter Results 4Health News:Conseco Reports Third Quarter Results 5Health News:Conseco Reports Third Quarter Results 6Health News:Conseco Reports Third Quarter Results 7Health News:Conseco Reports Third Quarter Results 8Health News:Conseco Reports Third Quarter Results 9Health News:Conseco Reports Third Quarter Results 10Health News:Conseco Reports Third Quarter Results 11Health News:Conseco Reports Third Quarter Results 12Health News:Conseco Reports Third Quarter Results 13Health News:Conseco Reports Third Quarter Results 14Health News:Conseco Reports Third Quarter Results 15Health News:Conseco Reports Third Quarter Results 16Health News:Conseco Reports Third Quarter Results 17Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:Golden Doctor of Chiropractic Elected President of the Colorado Chiropractic Association 2Health News:Scientists discover genetic variant associated with prostate cancer in African Americans 2
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
The Livewire steerable electrophysiology catheter is uniquely designed with an ergonomic handle and patented steering mechanism to provide smooth, precise catheter tip movement, even during lengthy e...
The Livewire cannulator offers improved access to the coronary sinus by combining the ergonomic Livewire steering mechanism with numerous specialized features....
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
Medicine Products: